Argenica Therapeutics Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.52%

Argenica Therapeutics Ltd (AGN) has an Asset Resilience Ratio of 0.52% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Argenica Therapeutics Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$50.00K

≈ $35.38K USD Cash + Short-term Investments

Total Assets

AU$9.54 Million

≈ $6.75 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Argenica Therapeutics Ltd's Asset Resilience Ratio has changed over time. See Argenica Therapeutics Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Argenica Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AGN market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$50.00K	0.52%
Total Liquid Assets	AU$50.00K	0.52%

Asset Resilience Insights

Limited Liquidity: Argenica Therapeutics Ltd maintains only 0.52% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Argenica Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Argenica Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	1.39%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shanghai Shen Lian Biomedical Corp SHG:688098	Biotechnology	3.87%

Annual Asset Resilience Ratio for Argenica Therapeutics Ltd (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Argenica Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.52%	AU$50.00K ≈ $35.38K	AU$9.54 Million ≈ $6.75 Million	--

pp = percentage points

About Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$15.45 Million

AU$21.84 Million AUD

Market Cap Rank

#25743 Global

#1180 in Australia

Share Price

AU$0.17

Change (1 day)

+0.00%

52-Week Range

AU$0.14 - AU$0.83

All Time High

AU$0.99